Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00735787 · ClinicalTrials.gov registry record · Phase 4
Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet
A Phase 4 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
NCT00735787: Completed Phase 4 study, sponsored by Abbott.
NCT00735787 is a Phase 4 study that has completed, run by Abbott. The registered enrollment target is 81 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00735787, a Phase 4 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
Study Summary
Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.
Primary Outcome
Number of subjects achieving a PGA of clear (representing no signs of plaque psoriasis) or almost clear (representing just perceptible erythema and scaling) at Week 16. The PGA is a 5-point scale used to measure the severity of disease at the time of the physician's evaluation of the subject. The degree of overall severity is rated as follows: 0-Clear, 1-Almost clear, 2-Mild, 3-Moderate, and 4-Severe.
Interventions
- BIOLOGICAL Adalimumab
- BIOLOGICAL Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-09 |
| Phase | Phase 4 |
What the finished NCT00735787 record still lists
NCT00735787 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Adalimumab is the first listed.
NCT00735787 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00735787 about?
NCT00735787 is a clinical study titled "Controlled Study of Humira in Subjects With Chronic Plaque Psoriasis of the Hands and/or Feet". Evaluate the efficacy and safety of a 16-week course of Humira (adalimumab) compared to placebo in adults with chronic plaque psoriasis of the hands and/or feet and the sustainability of response for 12 additional weeks.
What is the current status of trial NCT00735787?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2008-08. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00735787?
The interventions under investigation include: Adalimumab (BIOLOGICAL), Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT00735787?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00735787's enrollment target sits among peer trials
81 940th of 2000 higher than 1,055 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia